# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹193 Cr** Standalone Q4 (+8% QoQ, -19% YoY) · **₹246 Cr** Consolidated Q4 (+14% QoQ) * **EBITDA Margin:** **46%** Standalone Q4 · **33%** Consolidated Q4 · **37%** Consolidated FY26 * PAT Margin: 40% Standalone Q4 · 28% Consolidated Q4 · 24% Consolidated 12-month * **Gross Margin:** **~67%** Standalone Q4 (+200 bps QoQ) ## B. Revenue Growth & Volume Trends * **Sequential Recovery:** Top-line growth was primarily volume-led, signaling a rebound in customer offtake for flagship products despite a challenging YoY comparison. * **Annual Headwinds:** Full-year standalone contraction was driven by the loss of a major FMCG client for **4-MAP**, reduced offtake, and persistent pricing pressure on core offerings. * **Consolidated Stability:** Annual consolidated revenue remained resilient, as the scaling of the **HALS business** effectively offset weaknesses in the standalone portfolio. ## C. Margins & Profitability * **Operational Efficiency:** Standalone profitability remains robust, supported by a favorable product mix and a reduction in raw material costs to **33%** of revenue. * **HALS Turnaround:** The HALS segment achieved a significant milestone, moving from EBITDA neutral to positive territory despite sharp price spikes in **acetone and ammonia**. * **Earnings Quality:** Management confirmed margin expansion was driven by core operations rather than currency gains or inventory valuations, though results included an **INR 11 Cr** performance bonus reversal. ## D. Capital Allocation & Governance * **Promoter Alignment:** In a shareholder-friendly move, Promoter Directors capped their performance bonuses at **<1% of PBT**, well below their **4%** entitlement. * **Subsidiary Investment:** The company continued its aggressive growth pivot, deploying **INR 200 Cr** into its subsidiary this year, bringing total capital infusion to **INR 750 Cr**. * **Shareholder Returns:** The Board maintained its payout commitment with a final dividend of **INR 4 per share**. --- # 2. Product & Segment Performance ## A. Key Figures * **HALS Production Volume:** **>1,000 MT** Q4 FY26 (vs. ~350-360 MT 8 quarters ago) * **HALS Capacity Utilization:** **~40%** Standalone exit rate (March Quarter) * **Revenue Mix (FY):** **72%** Performance · **19%** Pharma-Agro · **9%** FMCG * **Clean Fino-Chem EBITDA:** **₹7 Cr** Q4 FY26 (**15%** Margin) * **Sequential Revenue Growth:** **8%** Consolidated (Volume-led) ## B. HALS Business Momentum * **Record Performance & Validation:** Achieved highest-ever quarterly revenue following the successful completion of long-term customer evaluations and trials. * **Strategic Export Pivot:** Successfully transitioned from a domestic import-substitute focus to a global profile, with exports now comprising **half** of select product sales across Europe, the US, and emerging markets in SE Asia and Latin America. * **Portfolio Premiumization:** Shifting focus toward higher-grade HALS and products with larger Total Addressable Markets (TAM), contributing to improved sequential margin profiles. * **Operational Scaling:** Quarterly volumes significantly exceeded previous monthly run-rate expectations, supported by in-house technology and an expanding distribution network maintaining higher safety stocks. ## C. Performance & Pharma * **New Capacity Monetization:** Commenced sales of **Hydroquinone (HQ) and Catechol** from the Performance Chemical 1 facility, achieving global quality benchmarks in both domestic and international markets. * **Segment Resilience:** Performance chemicals remain the primary revenue anchor; management is leveraging internal R&D to develop new products and mitigate intensifying global competition. * **HQ Strategy:** Clarified that new HQ production is being sold directly to the merchant market rather than being diverted for internal MEHQ manufacturing. ## D. Subsidiary Performance * **Profitability Inflection:** Clean Fino-Chem Limited achieved its first quarter of positive EBITDA, marking a successful transition from the previous quarter's breakeven. * **Operating Leverage:** Margin expansion is being driven by higher capacity utilization and the effective distribution of fixed costs over a larger volume base. * **Mix Optimization:** Subsidiary margins benefited from a favorable shift toward higher-grade HALS, which offset costs associated with the HQ-Catechol ramp-up. --- # 3. Manufacturing & Capacity ## A. Key Figures * **New Facility Utilization:** **10% to 15%** current capacity * **Optimization Timeline:** **1 to 2 quarters** for process norms · **2 quarters** for HQ catechol full-scale capacity * Captive Supply: All internal needs met by HQ catechol facility ## B. Utilization & Optimization * **Strategic Ramp-up:** Management is prioritizing the perfection of production yields and norms over immediate volume, resulting in currently low utilization levels at the new facility. * **Portfolio Expansion:** Plans are underway to debottleneck HALS lines and establish a dedicated line for **HALS 2020**, an intermediate essential for higher-grade specialty NOR-HALS products. * **Operational Complexity:** Capacity expansion in the chemical segment is noted as a complex, multi-month process, with current efforts focused on progressive quarter-on-quarter production increases. ## C. Backward Integration * **Import Substitution:** The stabilization of the Hydroquinone/Catechol plant has successfully replaced imports for **TBHQ and Veratrole**, effectively lowering raw material costs. * **Margin Enhancement:** The company is leveraging in-house processes and minimal CAPEX to integrate key starting materials for HALS, aiming to secure supply chains and improve profitability. * **Sourcing Shift:** In a significant strategic departure, the company has shifted the majority of its **phenol and acetone** sourcing to China. ## D. Facility Repurposing * **Strategic Pivot:** The planned pharma intermediate product has been abandoned due to technical issues; instead, existing pharma plants have been repurposed for HALS intermediates. * **Competitive Positioning:** The conversion of the **DHDT facility** into a HALS intermediate plant is designed to eliminate dependence on Chinese suppliers and provide a structural cost advantage. --- # 4. Competitive Position ## A. Key Figures * **Global Anisole Market Size:** **~25,000 tonnes** total addressable market ## B. Market Share Defense * **Strategic Pricing Resilience:** Maintained market share in the MEHQ segment through proactive pricing actions, resulting in stable revenue despite intensified competition from Chinese players. * **Defensive Moats:** Leveraging process efficiency and backward integration to protect domestic and international positions; notably, captive consumption of anisole insulates the firm from Chinese market volatility. * **Competitive Landscape:** Management remains confident against domestic entrants (e.g., Vinati Organics, Gem Aromatics) and global peers, attributing new domestic competition to a desire to replicate the company’s high-margin profile. * **European Opportunity:** Operational pressures on European competitors are creating a strategic window to capture additional market volume and realize improved end-product pricing. ## C. Global Supplier Status * **HALS Market Recognition:** Established status as a reputable global supplier of HALS has triggered a significant uptick in inbound interest from international clientele. * **Market Leadership:** Currently positioned as the largest producer and consumer of Anisole both in India and globally. * **Go-to-Market Strategy:** Prioritizing commercial sales via direct distribution and end-customers over lower-margin contract manufacturing for large European majors like BASF. ## D. Technology & Innovation * **Proprietary Process Advantage:** Utilization of **vapor phase technology** for Anisole manufacturing remains a key differentiator; management notes uncertainty regarding whether domestic competitors have successfully replicated this specific process. --- # 5. Demand & Pricing ## A. Key Figures * **Blended Realization:** **₹460/kg** Current Quarter (vs. ₹420–430/kg QoQ) * **Target Realization:** **$7.00–$7.50/kg** Long-term blended goal ## B. Realization Trends * **Sequential Pricing Strength:** Blended realizations saw a notable uptick compared to the previous quarter's range. * **Competitive Differentiation:** Proprietary **vapor phase route** for MEHQ production provides superior realizations and ESG compliance over traditional Chinese HQ-based methods. ## C. Cost Pass-through & Contract Dynamics * **Variable Pricing Power:** Successfully passed through rising phenol costs to spot customers, though long-term contracts remain a temporary headwind to immediate recovery. * **Contractual Lag:** Management utilizes **half-yearly and full-yearly** contract cycles, with margin recovery expected as these agreements undergo scheduled renegotiations. * **HALS Market Strategy:** Competitiveness in the HALS segment is being driven by volume scaling and operational efficiencies to offset raw material volatility. --- # 6. Risks & Chemical Macro ## A. Key Figures * **Raw Material Volatility:** **2x** peak price increases in commodity base products * **Market Pressure Duration:** **3 to 4 months** of excess HQ capacity impact from China ## B. Geopolitical & Macro Outlook * **Challenging Operating Environment:** FY26 performance was tempered by muted customer offtake, pricing pressures, and tariff-related uncertainties. * **Tricky FY27 Outlook:** Management anticipates a difficult year ahead, citing heavy dependence on global supply positions and crude oil price volatility. ## C. Chinese Price Arbitrage & Competitive Dynamics * **Strategic Import Advantage:** A substantial pricing differential between China and India allows for competitive commodity imports that outperform local Indian suppliers. * **Persistent Pricing Arbitrage:** Chinese commodity prices remained highly competitive through **June**, sustained by a disparity in price increases between China and the rest of the world. * **Market Defense:** Despite significant capacity-driven pricing pressure from China, the company is defending its MEHQ market position via technical strategies and pricing recalibration. * **Input Cost Risk:** A primary threat to competitiveness remains the potential for Chinese producers to access cheaper crude or raw materials relative to Indian manufacturers. ## D. Raw Material Volatility * **Unstable Benchmarks:** While some base products saw extreme price spikes, management does not view these volatile peaks as stable transactional benchmarks for the long term. --- # 7. Guidance & Outlook ## A. Key Figures * **FY27 Capex Budget:** **₹80 Cr** to **₹100 Cr** for Clean Science and Technology Limited * **Clean Fino-Chem Investment:** **₹200 Cr** enabling resolution for pipeline and greenfield projects ## B. Strategic Focus & Commercialization * **Macro Positioning:** Management anticipates tailwinds from a projected inflationary environment, drawing parallels to the favorable trends observed in **FY23**. * **Performance Chemical 2 Timeline:** Commercialization is now slated for **September 2026**, following delays caused by labor shortages linked to energy price volatility. * **Water Treatment Validation:** The Performance 2 product line expects validation in **Q3**, with initial commercial contributions in **Q4** and a meaningful volume ramp-up deferred to **FY28**. ## C. Capex & Expansion Strategy * **Growth Funding:** Significant capital allocation is secured for Clean Fino-Chem to support long-term capacity expansion, though specific product details remain in planning. * **Investment Phasing:** Beyond the immediate fiscal budget, additional expansionary investments are projected to materialize in the **latter half of FY27**.